Clinical and laboratory characteristics of 30 patients with SGLT2 inhibitor associated JAK2 wild-type erythrocytosis
| Variables at time of erythrocytosis evaluation . | Data (N = 30) . |
|---|---|
| Age in years, median (range) | 64 (29-81) |
| Men, n (%) | 20 (67) |
| SGLT2 inhibitor and dose, n (%) Canagliflozin 300 mg Canagliflozin 100 mg Canagliflozin 100 mg/Empagliflozin* 10 mg Canagliflozin 100 mg/Dapagliflozin* 10 mg Canagliflozin 100 mg/Empagliflozin 10mg/Dapagliflozin* 10 mg Empagliflozin 10 mg Empagliflozin 12.5 mg Empagliflozin 25 mg Dapagliflozin 10 mg Empagliflozin/linagliptin 25/5 mg Duration of therapy in years, median (range) | 6 (20) 3 (10) 2 (7) 1 (3) 1 (3) 6 (20) 1 (3) 7 (23) 2 (7) 1 (3) 1.7 (0.2-5.7) |
| Additional predisposition for erythrocytosis, n (%) OSA OSA+smoking Smoking | 8 (27) 5 (17) 2 (7) 1 (3) |
| Prior thrombosis, n(%)† Major arterial thrombosis Major venous thrombosis | 4 (13) 1 (3) 3 (10) |
| Baseline hemoglobin g/dL, median (range)‡ Male Female | 15.8 (13.4-16.9) 16 (13.4-16.9) 14.5 (13.4-16.5) |
| Baseline hematocrit %, median (range)§ Male Female | 45.7 (39-48.2) 46.1 (40.7-48.2) 42.6 (39-46.3) |
| Peak hemoglobin g/dL, median (range) Male Female | 17.9 (15.3-19.8) 18.3 (16.5-19.8) 16.9 (15.3-18) |
| Peak hematocrit %, median (range) Male Female Increase in hematocrit %, median (range) Time to peak hematocrit in months, median (range) | 52.9 (48-60.1) 54.4 (50.7-60.1) 51.2 (48-52.8) 7.4 (2-14.1) 11.5 (1-57) |
| Serum erythropoietin mIU/mL, median (rangeǁ | 10.3 (6.1-37.3) |
| Absolute reticulocyte count, median (range)¶ | 83.1 (83.1-135) |
| Serum ferritin μg/L, median (range)# | 54.5 (9-840) |
| Treatment, n (%) Phlebotomy/blood donation Antiplatelet therapy (aspirin or clopidogrel) Anticoagulation | 7 (23) 14 (47) 5 (17) |
| Outcomes | |
| Follow-up in years, median (range) | 2.2 (0.2-5.7) |
| Thrombosis during therapy, n (%) Major arterial thrombosis, n (%) Major venous thrombosis, n (%) | 2 (7) 2 (7) 0 (0) |
| Treatment discontinuation, n (%) Reason for discontinuation, n (%) Erythrocytosis Poorly controlled diabetes mellitus Yeast infection | 7 (23) 3 (43) 3 (43) 1 (14) |
| Resolution of erythrocytosis, n (%)** Median hemoglobin g/dL, median (range) Median hematocrit %, median (range) Time to resolution in months, median (range) | 6 (100) 15.3 (14.5-16.1) 45.4 (42.5-47) 2 (1-12) |
| Variables at time of erythrocytosis evaluation . | Data (N = 30) . |
|---|---|
| Age in years, median (range) | 64 (29-81) |
| Men, n (%) | 20 (67) |
| SGLT2 inhibitor and dose, n (%) Canagliflozin 300 mg Canagliflozin 100 mg Canagliflozin 100 mg/Empagliflozin* 10 mg Canagliflozin 100 mg/Dapagliflozin* 10 mg Canagliflozin 100 mg/Empagliflozin 10mg/Dapagliflozin* 10 mg Empagliflozin 10 mg Empagliflozin 12.5 mg Empagliflozin 25 mg Dapagliflozin 10 mg Empagliflozin/linagliptin 25/5 mg Duration of therapy in years, median (range) | 6 (20) 3 (10) 2 (7) 1 (3) 1 (3) 6 (20) 1 (3) 7 (23) 2 (7) 1 (3) 1.7 (0.2-5.7) |
| Additional predisposition for erythrocytosis, n (%) OSA OSA+smoking Smoking | 8 (27) 5 (17) 2 (7) 1 (3) |
| Prior thrombosis, n(%)† Major arterial thrombosis Major venous thrombosis | 4 (13) 1 (3) 3 (10) |
| Baseline hemoglobin g/dL, median (range)‡ Male Female | 15.8 (13.4-16.9) 16 (13.4-16.9) 14.5 (13.4-16.5) |
| Baseline hematocrit %, median (range)§ Male Female | 45.7 (39-48.2) 46.1 (40.7-48.2) 42.6 (39-46.3) |
| Peak hemoglobin g/dL, median (range) Male Female | 17.9 (15.3-19.8) 18.3 (16.5-19.8) 16.9 (15.3-18) |
| Peak hematocrit %, median (range) Male Female Increase in hematocrit %, median (range) Time to peak hematocrit in months, median (range) | 52.9 (48-60.1) 54.4 (50.7-60.1) 51.2 (48-52.8) 7.4 (2-14.1) 11.5 (1-57) |
| Serum erythropoietin mIU/mL, median (rangeǁ | 10.3 (6.1-37.3) |
| Absolute reticulocyte count, median (range)¶ | 83.1 (83.1-135) |
| Serum ferritin μg/L, median (range)# | 54.5 (9-840) |
| Treatment, n (%) Phlebotomy/blood donation Antiplatelet therapy (aspirin or clopidogrel) Anticoagulation | 7 (23) 14 (47) 5 (17) |
| Outcomes | |
| Follow-up in years, median (range) | 2.2 (0.2-5.7) |
| Thrombosis during therapy, n (%) Major arterial thrombosis, n (%) Major venous thrombosis, n (%) | 2 (7) 2 (7) 0 (0) |
| Treatment discontinuation, n (%) Reason for discontinuation, n (%) Erythrocytosis Poorly controlled diabetes mellitus Yeast infection | 7 (23) 3 (43) 3 (43) 1 (14) |
| Resolution of erythrocytosis, n (%)** Median hemoglobin g/dL, median (range) Median hematocrit %, median (range) Time to resolution in months, median (range) | 6 (100) 15.3 (14.5-16.1) 45.4 (42.5-47) 2 (1-12) |
OSA, obstructive sleep apnea.
SGLLT2 inhibitor at the time of erythrocytosis evaluation.
Major arterial thrombosis included cerebrovascular accident, transient ischemic attack, myocardial infarction, angina, peripheral arterial thrombosis. Major venous thrombosis included deep vein thrombosis, pulmonary embolism, splanchnic vein thrombosis.
Reference range: women (11.6-15 g/dL), men (13.2-16.6 g/dL).
Reference range: women (35.5% to 44.9%), men (38.3% to 48.6%).
n = 27. Reference range: 2.6-18.5 mIU/mL.
n = 3. Reference range: 30.4-110.9 × 109/L.
n = 9. Reference range: 24-336 μg/L.
n = 6.